Literature DB >> 8625256

Increased tubulin acetylation accompanies reversion to stable ploidy in vincristine-resistant CCRF-CEM cells.

M Geyp1, C M Ireland, S M Pittman.   

Abstract

The T-cell leukemia line CCRF-CEM is unstable with respect to ploidy, whereas a vincristine-resistant subline, CEM/VCR R, maintains a stable pseudodiploid karyotype. Ploidy change in the parental cells requires the involvement of two cell cycle lesions. The first, in mitosis, prevents cell division after S-phase. The second, in G1, allows a cell with 4N DNA content to re-enter S-phase. We examined differences in expression of tubulin, a major component of the mitotic spindle and the cellular target for vincristine, between the two cell lines. Levels of the beta III isotype were decreased and levels of acetylated alpha-tubulin, a marker for microtubule stability, were increased in the CEM/VCR R cells relative to the parental line, which suggests that the CEM/VCR R cells have a more stable mitotic spindle. Both cell lines exhibit some level of constitutive expression of p53 and c-myc. Constitutive expression of and mutant p53 would contribute to the failure of these cells to recognise G1 checkpoints. Therefore, G1 checkpoint failure and the intrinsically less stable mitotic spindle in the CCRF-CEM cells may contribute to the observed ploidy instability. Conversely, the presence of markers of microtubule stability in the CEM/VCR R cells would predispose them to maintain their ploidy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625256     DOI: 10.1016/0165-4608(95)00235-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  Nakiterpiosin targets tubulin and triggers mitotic catastrophe in human cancer cells.

Authors:  Jen-Hsuan Wei; Joachim Seemann
Journal:  Mol Cancer Ther       Date:  2010-12-07       Impact factor: 6.261

2.  Centaurin-α₂ interacts with β-tubulin and stabilizes microtubules.

Authors:  Paola Zuccotti; Daniele Cartelli; Michela Stroppi; Vittorio Pandini; Marco Venturin; Alessandro Aliverti; Elena Battaglioli; Graziella Cappelletti; Paola Riva
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.